1 patent currently held
38 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
9 more records may belong here and await a decision; they are not counted.
The next term ends in Oct 2042. from the record
Of the 38 now held by other companies, 9 were conveyed to Denali Therapeutics Inc. in the filing they arrived in, and 29 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Oct 2042
Next term end
1
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 1 of the currently held patents qualifies as notable.
Formerly held, still cited
Notable
Ends Feb 2037 · High confidence
The most cited patent in this portfolio, cited by 79 later US patents, top 5% of utility patents granted in 2017 in our data. Protection runs to 2037.
conveyed to Denali Therapeutics Inc.
Also notable
Ends no later than Aug 2029 · Medium confidence
Cited by 46 later US patents, top 25% of utility patents granted in 2013 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2029. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
now held by Salix Pharmaceuticals, Inc.
Also notable
Ends Feb 2033 · High confidence
Renewed at every maintenance window since the 2014 grant; no more fees are due before its term ends in 2033.
now held by Journey Medical Corporation
Fee deadlines
No maintenance fee falls due on this company's record before Nov 10, 2027.
Recent changes
- 1 of the patents on this record was granted since Aug 16, 2026
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Showing 1 to 1 of 1
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 12,759,981 | Cholinate of 2-(1-Cyclobutyl-1H-PYRAZOL-4-YL)-5-[([{1-[2-Fluoro-4-(TRIFLUOROMETHYL)-PHENYL]CYCLOPROPYL}CARBONYL)AMINO]BENZOIC Acid held by Bayer Aktiengesellschaft In force · High confidence | In force | High confidence |
Also on record, not counted in the 1: 38 patents in force now held by others · 12 patents ended · 2 applications pending · 19 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
6 terminal disclaimers are on file with no resolved reference. No cap is applied and none is guessed
12 computed term dates come from a chain with an unresolved parent. A continuity parent has not yet been fetched from USPTO's records. The term is dated from this application's own claim; no earlier date is assumed until the parent is resolved.